133 related articles for article (PubMed ID: 31839880)
21. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
[TBL] [Abstract][Full Text] [Related]
22. Molecular Status of
Jafarian A; Jafaripour M; Gharib M; Salehi M; Mohamadian Roshan N; Etemad S; Mirshekar K; Sheikhi M; Heidari M; Ahmadian B; Khoshnegah Z; Ayatollahi H; Siyadat P
Iran J Pathol; 2023; 18(2):134-139. PubMed ID: 37600581
[TBL] [Abstract][Full Text] [Related]
23. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
24. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component.
Slomovitz BM; Caputo TA; Gretz HF; Economos K; Tortoriello DV; Schlosshauer PW; Baergen RN; Isacson C; Soslow RA
Am J Surg Pathol; 2002 May; 26(5):592-600. PubMed ID: 11979089
[TBL] [Abstract][Full Text] [Related]
25. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
26. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Singer G; Oldt R; Cohen Y; Wang BG; Sidransky D; Kurman RJ; Shih IeM
J Natl Cancer Inst; 2003 Mar; 95(6):484-6. PubMed ID: 12644542
[TBL] [Abstract][Full Text] [Related]
27. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
Rollins SE; Young RH; Bell DA
Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
[TBL] [Abstract][Full Text] [Related]
28. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
29. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
30. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
31. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.
Parker RL; Clement PB; Chercover DJ; Sornarajah T; Gilks CB
Int J Gynecol Pathol; 2004 Jul; 23(3):265-72. PubMed ID: 15213603
[TBL] [Abstract][Full Text] [Related]
32. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
33. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
34. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
36. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
37. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
38. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kjaerbye-Thygesen A; Andersen KK; Tabor A; Kurman RJ; Kjaer SK
Gynecol Oncol; 2014 Aug; 134(2):267-73. PubMed ID: 24924123
[TBL] [Abstract][Full Text] [Related]
39. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
40. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
